BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32976902)

  • 1. Rational design of a minimalist nanoplatform to maximize immunotherapeutic efficacy: Four birds with one stone.
    Zhou S; Shang Q; Wang N; Li Q; Song A; Luan Y
    J Control Release; 2020 Dec; 328():617-630. PubMed ID: 32976902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cold to Hot: Rational Design of a Minimalist Multifunctional Photo-immunotherapy Nanoplatform toward Boosting Immunotherapy Capability.
    Zhang D; Zhang J; Li Q; Song A; Li Z; Luan Y
    ACS Appl Mater Interfaces; 2019 Sep; 11(36):32633-32646. PubMed ID: 31429272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering a photosensitizer nanoplatform for amplified photodynamic immunotherapy via tumor microenvironment modulation.
    Zhou Y; Ren X; Hou Z; Wang N; Jiang Y; Luan Y
    Nanoscale Horiz; 2021 Feb; 6(2):120-131. PubMed ID: 33206735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoengineering a metal-organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells.
    Fan Q; Zuo J; Tian H; Huang C; Nice EC; Shi Z; Kong Q
    J Exp Clin Cancer Res; 2022 May; 41(1):162. PubMed ID: 35501823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.
    Qian F; Villella J; Wallace PK; Mhawech-Fauceglia P; Tario JD; Andrews C; Matsuzaki J; Valmori D; Ayyoub M; Frederick PJ; Beck A; Liao J; Cheney R; Moysich K; Lele S; Shrikant P; Old LJ; Odunsi K
    Cancer Res; 2009 Jul; 69(13):5498-504. PubMed ID: 19491279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
    Ding Y; Sun Z; Gao Y; Zhang S; Yang C; Qian Z; Jin L; Zhang J; Zeng C; Mao Z; Wang W
    Adv Mater; 2021 Aug; 33(34):e2102188. PubMed ID: 34278622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An albumin-bound drug conjugate of paclitaxel and indoleamine-2,3-dioxygenase inhibitor for enhanced cancer chemo-immunotherapy.
    Hu Z; Zheng B; Xu J; Gao S; Lu W
    Nanotechnology; 2020 May; 31(29):295101. PubMed ID: 32203949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6 and indoleamine-2,3-dioxygenase as potential adjuvant targets for Papillomavirus-related tumors immunotherapy.
    Pagni RL; Souza PDC; Pegoraro R; Porchia BFMM; da Silva JR; Aps LRMM; Silva MO; Rodrigues KB; Sales NS; Ferreira LCS; Moreno ACR
    Front Immunol; 2022; 13():1005937. PubMed ID: 36405719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunogenic cell death via photo-pyroptosis with light-sensitive Indoleamine 2,3-dioxygenase inhibitor conjugate.
    Lu Y; Xu F; Wang Y; Shi C; Sha Y; He G; Yao Q; Shao K; Sun W; Du J; Fan J; Peng X
    Biomaterials; 2021 Nov; 278():121167. PubMed ID: 34624752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy.
    Zhang X; Liang Q; Cao Y; Yang T; An M; Liu Z; Yang J; Liu Y
    J Nanobiotechnology; 2024 Jun; 22(1):319. PubMed ID: 38849938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer.
    Zang X; Song J; Yi X; Piyu J
    J Mater Chem B; 2022 Mar; 10(12):2019-2027. PubMed ID: 35254372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
    Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
    EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
    Li F; Zhao Y; Wei L; Li S; Liu J
    Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injectable Micelle-Incorporated Hydrogels for the Localized Chemo-Immunotherapy of Breast Tumors.
    Qin X; He L; Feng C; Fan D; Liang W; Wang Q; Fang J
    ACS Appl Mater Interfaces; 2021 Oct; 13(39):46270-46281. PubMed ID: 34550685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
    Liu D; Chen B; Mo Y; Wang Z; Qi T; Zhang Q; Wang Y
    Nano Lett; 2019 Oct; 19(10):6964-6976. PubMed ID: 31518149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer.
    Maletzki C; Wiegele L; Nassar I; Stenzel J; Junghanss C
    J Immunother Cancer; 2019 Jan; 7(1):8. PubMed ID: 30630527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prodrug-Based Versatile Nanomedicine for Enhancing Cancer Immunotherapy by Increasing Immunogenic Cell Death.
    Bai S; Yang LL; Wang Y; Zhang T; Fu L; Yang S; Wan S; Wang S; Jia D; Li B; Xue P; Kang Y; Sun ZJ; Xu Z
    Small; 2020 May; 16(19):e2000214. PubMed ID: 32309900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.
    Yu J; Du W; Yan F; Wang Y; Li H; Cao S; Yu W; Shen C; Liu J; Ren X
    J Immunol; 2013 Apr; 190(7):3783-97. PubMed ID: 23440412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polypeptide nanoformulation-induced immunogenic cell death and remission of immunosuppression for enhanced chemoimmunotherapy.
    Feng X; Xu W; Liu J; Li D; Li G; Ding J; Chen X
    Sci Bull (Beijing); 2021 Feb; 66(4):362-373. PubMed ID: 36654416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.
    Johnson TS; Mcgaha T; Munn DH
    Adv Exp Med Biol; 2017; 1036():91-104. PubMed ID: 29275467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.